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methods. 1%/1mm and local normalization is able to detect 
all type of errors (1%/1mm with global normalization is not 
able to detect the systematic shift of 2,5 mm), but it could 
overestimates some errors that have not clinical impact. In 
the table, we reported the results of sensitivity and 
specificity of PF to detect clinically relevant errors.  
 
 
 
Conclusion: EPID device and PF software can be confidently 
used in clinical routine to detect dosimetric, geometrical and 
anatomical discrepancies. The possibility of this in vivo 
evaluation and the potentiality of this new system have a 
very positive impact on improving daily patient QA .  
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Purpose or Objective: The aim of this work is to evaluate 
the perturbed DVHs generated from Tomotherapy dose 
distributions according to the dose discrepancies detected 
with pre-treatment measurements. Through perturbed DVHs 
data, sensitivity and specificity of gamma passing rate (%GP) 
were calculated to evaluate if Gamma Index (GI) metric 
correctly differentiates the high dose error plans from low 
dose error plans. In the literature GI was found to be a poor 
predictor of dosimetric accuracy with planar and volumetric 
dosimeters for IMRT and VMAT techniques, we evaluate if this 
lack of prediction of GI method is valid also for Tomotherapy 
plans. 
 
Material and Methods: 12 patients for prostate cancer (P), 
and 12 for head and neck (HN) cancer, were enrolled in the 
study. All the treatments were delivered using the Helical 
Tomotherapy Hi-ART system (Accuray, Inc., Sunnyvale, CA). 
Pre-treatment QA measurements were performed by using 
the diode array ArcCHECKTM and perturbed DVHs were 
obtained with the 3DVH software (both by Sun Nuclear 
Corporation, Melbourne, FL). Measured and calculated dose 
distributions were compared using the global and local GI 
method with 2%/2 mm, and 3%/3 mm criteria. Low-dose 
thresholds (TH) of 10% and 30% were applied and analyzed. 
Percentage dose differences between DVHs, obtained by TPS 
and by 3DVH were calculated. A %GP equal to 95% and a 
mean absolute DVH 3% dose error were used as thresholds to 
calculate sensitivity and specificity. In order to quantify the 
sensitivity and specificity of GI method, we calculated the 
number of false negative (high Tomotherapy QA passing rates 
indicate large errors in anatomy dose metrics), true positive 
(low Tomotherapy QA passing rates do imply large errors in 
anatomy dose metrics), true negative (high Tomotherapy QA 
passing rates did imply small errors in anatomy dose metrics) 
and false positive (low Tomotherapy QA passing rates did 
imply small errors in anatomy dose metrics). 
 
Results: We found the higher sensitivity (0.55) for global 
normalization with 3%/3mm and TH=30% and the higher 
specificity (0.67) with 3%/3mm for global normalization, both 
for TH 10% and 30%. Instead we obtained the poorer 
sensitivity (0) with 2%/2mm, local normalization, and TH=10% 
because the threshold of 95% is too high for 2%/2mm and 
local normalization. We observed the poorer specificity 
(0.39) for 3%/3mm, local normalization, both for TH=10% and 
30%. For global normalization, 3%/3mm sensitivity and 
specificity were always higher than those of 2%/2mm 
criterion. 
 
Conclusion: The low sensitivity and specificity values of GI 
method, for all the applied criteria, show that the gamma 
index metric have disputable predictive power for per-
patient Tomotherapy QA. 
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Purpose or Objective: The gamma index (γ) is a common 
method for comparing measured and predicted dose 
distributions. The percentage of points passing with γ<1 (Γ) is 
the most frequently reported analysis metric. However, the 
use of Γ has been reported to have weak correlation against 
clinically relevant metrics and the result also varies 
depending on the Quality Assurance (QA) system 
configuration and software used. Other metrics could be 
extracted from the γ map but have not been rigorously 
evaluated in the literature to address appropriate acceptance 
values. This study has developed a methodology to evaluate 
the suitability of the mean, median, maximum, or near-
maximum γ metrics (γmean, γmedian, γmax, γ1%) and their 
acceptance criteria. 
 
Material and Methods: Investigations were performed using 
simulated data with deliberate changes created in a virtual 
phantom test. The changes included: dose deviations of -5% 
to 5% in 1% steps; and MLC offsets of 1–5mm in 1mm steps. An 
in-house Matlab-based software was used to perform γ 
analysis to extract different metrics. The primary PTV mean 
(PTVmean) and organ at risk maximum (OARmax) dose 
deviations were extracted from the changed plans. The γ 
metrics were correlated against PTVmean and OARmax for 
global γ passing criteria of 3%/2mm (20% threshold relative to 
a point in high dose low gradient). Acceptance criteria 
needed to predict a dose deviation >±3%, for 3%/2mm, were 
assessed using Receiver Operator Characteristic (ROC) 
analysis and assuming 100% sensitivity. The area under the 
ROC curve (AUC) was assessed for each γ metric to assess 
statistical reliability. Since the γ calculation can give varying 
results between different QA systems, the robustness of the 
proposed methodology was tested by varying γ passing 
criteria as well calculating in 2D planes and 3D volumes. 
 
Results: The γmean, γmedian and γ1% metrics had the 
strongest Pearson correlation coefficient (ρ) against the 
PTVmean (ρ>0.95, p<0.01); (Fig. 1). The Γ had a weaker 
correlation of ρ=-0.76. These metrics had ROC AUC>0.9 
(p<0.01) showing statistically strong accuracy for predicting a 
PTVmean deviation >±3% for 3%/2mm. Optimal acceptance 
criteria for achieving 100% sensitivity are shown in Table 1. 
The γmax had the best correlation against OARmax (ρ> 0.8, 
p<0.01) and the AUC was >0.9 and showed that points with 
γ>1.1 may be associated with a >3% increase in the OARmax. 
Correlations between different γ passing criteria were 
statistically strong at >0.95 (p<0.01) as were correlations 
between 2D & 3D γ calculations, indicating the robustness of 
the methodology to the variability in γ calculation that could 
be caused by QA system configuration and software 
implementation. 
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Conclusion: The γmean, γmedian and γ1% metrics have 
potential to be used as parameters to predict PTV dose 
deviations and had better correlation than the passing rate. 
However for OAR dose deviations, the γmax showed the 
strongest correlation with DVH deviations. This methodology 
is robust the variability in γ calculation. 
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Purpose or Objective: Aim of this study is the evaluation of 
build-up and superficial doses for a Head&Neck treatment, 
delivered by Helical TomoTherapy (HT). Measurements were 
carried out by two different dosimeters (radiochromic films 
and a synthetic single crystal diamond detector) and 
compared with TPS data. Build-up dose profiles and 
superficial dose points were estimated. The reliability of the 
TPS in these critical regions was assessed, giving an insight 
into a subject on which quite contradictory results are 
reported in the literature. 
 
Material and Methods: A home modified Anderson Rando 
phantom was employed to house the detectors. As shown in 
figure (a), two slices of the phantom neck were removed and 
replaced with a PMMA artificial neck, with a hole inside to 
mimic the trachea. This allowed to measure dose profiles and 
superficial dose points with geometrical and scattering 
conditions similar to the ones taking place when a real 
patient is treated. Gafchromic EBT3 films (Ashland Inc., 
Wayne, NJ) were sandwiched inside the neck in oder to 
measure dose profiles and attached to the neck surface for 
superficial dose point assessment. PTW-Frieburg 
microDiamond (mD) was positioned inside drilled holes at 
different known distances respect to the phantom surface.  
 
 
 
Results: In figure (b) one of the measured dose profiles by 
EBT3 and mD is reported, along the Antero-Posterior 
direction, in the range 0-30 mm (distance from the phantom 
surface). TPS data are also shown, as black dots, with an 
associated error of ± 0.9 mm, half of the lateral dimension of 
the calculation pixel (fine grid). The prescribed dose is 
reached within approximately 4 mm from the phantom 
surface and it does not show any significant variation going 
further inside the neck, in particular at the PMMA/air 
interface, in correspondence of the trachea starting point. 
A 1D threshold criterion of 3%/mm was adopted in order to 
discriminate between high and low gradient zones. Dose 
differences (DD) measured by mD are within 2.5% respect to 
TPS, in the low gradient region, while a maximum distance-
to-agreement (DTA) of 0.9 mm is found for the same device, 
in the high gradient region. EBT3 profile shows a more noisy 
behavior, with a maximum DD of 3.8% in the low gradient 
portion of the profile, while DTA is less than 1 mm in the high 
gradient zone. The superficial dose measurement by EBT3 
film is characterized by a DTA of 0.5 mm and a DD of 5.2%.  
 
Conclusion: Build-up dose profiles measured by the two 
dosimeters show the same behavior and are in agreement 
with TPS data; deviations are well within the reference 
tolerance level. The investigation carried out in this work 
offers the possibility of studying the TPS behavior not only in 
terms of dose difference, as carried out for in vivo 
measurements, but also taking into account a “spatial 
displacement”, to be compared with patient (and/or 
dosimeter) positioning uncertainties. 
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Purpose or Objective: To evaluate experimentally the 
accuracy of the dose calculation algorithm AcurosXB in small-
field highly modulated Volumetric Modulated Arc Therapy 
(VMAT). 
 
Material and Methods: The Octavius 1000SRS detector array 
inserted in the rotational Octavius4D phantom (PTW) was 
used, consisting of 977 liquid-filled ion chambers covering an 
area of 11×11cm2. The detector size (2.3×2.3×0.5mm3) and 
the center-to-center distance of the detectors (2.5mm in the 
inner 5.5×5.5cm2 area) are important parameters for correct 
spatial measurement of complex dose distributions with 
steep dose gradients. Clinical treatment plans (n=28), 
characterized by small treatment volumes, 6 and 10MV 
photon beams, and fraction doses between 2.75-30 Gy, were 
projected on the phantom CT data set and recalculated in 
the Eclipse TPS v11 (Varian Medical Systems) using AcurosXB 
with a calculation grid size of 2.5mm and 1mm (field sizes 
<3x3cm2). All measurements were done on a Varian 
TrueBeamSTx linac. The irradiation technique used was 
